## Perspective A: The Elderly Patient Advocate

A tool that systematically under-treats people 75+ is not a “subtle” problem; it is predictable harm to a protected, vulnerable group. Elderly patients already face dismissal, undertesting, and undertreatment. Deploying an algorithm that amplifies that pattern violates basic dignity and equal concern. The hospital must immediately add a hard safety layer: mandatory clinician review for all 75+ recommendations, with an option to override toward standard-of-care treatment. Patients and families deserve disclosure and a pathway to appeal decisions. If resources are tight, triage must be transparent and justified—not quietly encoded in a model.

## Perspective B: The Hospital Administrator

My duty is to run a safe hospital that helps as many patients as possible with finite staff and budget. This system improved outcomes for most groups; reverting would predictably harm thousands. But continuing without guardrails exposes us to reputational damage, malpractice claims, and moral injury among clinicians. The rational path is mitigation, not abandonment: add an elderly-review protocol, adjust thresholds for 75+, and measure outcomes weekly. We can negotiate with the vendor for remediation and cost sharing, and seek grants for a rapid audit. The goal is to preserve aggregate benefit while shrinking the concentrated harm.

## Perspective C: The AI Developer

If my model causes systematically worse outcomes for 75+ patients, I have an obligation to disclose, diagnose, and fix it—fast. The bias may come from training data imbalance, label leakage, or an objective that optimized average utility while underweighting older cohorts. First, we should reproduce the disparity, quantify it (calibration, false negatives, treatment intensity), and publish a corrective action plan to the hospital. Then we can implement cohort-aware calibration, fairness constraints, and monitoring with drift alarms. A responsible developer also supports interim “human-in-the-loop” policies and documents limitations so clinicians understand when the model is likely to fail.

## Perspective D: The Medical Ethics Board Member

The four principles pull in different directions here. Beneficence favors keeping the system if it improves overall outcomes; non-maleficence objects to knowingly continuing harm to a specific group. Justice demands that age not become a quiet basis for lesser care, and autonomy requires disclosure so patients can meaningfully consent to AI-assisted decisions. Precedent matters: if we normalize “majority benefit, minority harm,” we invite future deployments that sacrifice other groups. The ethically defensible stance is conditional use: keep the tool only with immediate safeguards for 75+ patients, transparent communication, and a firm timeline to remediate or retire the model if disparities persist.

## Perspective E: The Health Insurance Actuary

Systemic risk is the lens: liability, long-term cost, and incentives. Under-treating elderly patients can increase downstream costs (avoidable complications, readmissions) and trigger regulatory scrutiny for discrimination. Even if the hospital can’t buy a replacement, it can reduce risk cheaply by adding protocols that raise treatment intensity for 75+ and documenting rationale. Payers may support targeted mitigation if it lowers total cost of care, and they will demand evidence: stratified outcomes, calibration by age, and audit trails. A well-documented mitigation plan also protects against litigation by showing the hospital recognized the risk and acted proportionately.

## Synthesis and Recommendation

**Core tensions:** (1) **Beneficence vs non-maleficence**—the system helps many, yet it harms a defined minority. (2) **Utilitarian aggregation vs justice**—maximizing total outcome can still be unfair if the burden falls on 75+ patients. (3) **Speed and cost vs transparency and consent**—quiet deployment is operationally easy, but ethically brittle.

Each perspective gets something right: the advocate centers equal dignity and the reality of age-based neglect; the administrator sees the practical catastrophe of ripping out a beneficial system; the developer highlights that “bias” is a fixable engineering and governance problem; the ethics board insists that precedent and informed autonomy matter; the actuary reminds us that harm today becomes liability and expense tomorrow.

**Recommendation:** Keep the system in place, but immediately implement a mandatory 75+ clinician-review-and-override policy, lower the model’s treatment threshold for 75+, and run weekly stratified audits (outcomes, false negatives, treatment intensity). Require the vendor to deliver a remediation patch on a short timeline, and publicly disclose to patients that AI support is used and how clinicians can override it.

This is justified because it preserves the majority benefit while directly targeting the concentrated harm and building accountability. **Trade-offs/costs:** more clinician time, more false positives and overtreatment risk for 75+ patients, and near-term budget spent on monitoring and audit capacity. However, those sacrifices are preferable to quietly accepting preventable harm and the long-run cost of eroded trust.
